A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage
- Postato il 9 aprile 2026
- Di CNBC
- 0 Visualizzazioni
A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.